Stockscreener 앱 받기
11.35
2.07%
-0.24
전일 마감가:
$11.59
열려 있는:
$11.65
하루 거래량:
1.86M
Relative Volume:
2.30
시가총액:
$4.83B
수익:
$4.79B
순이익/손실:
$-317.00M
주가수익비율:
-12.47
EPS:
-0.91
순현금흐름:
$-59.00M
1주 성능:
-16.24%
1개월 성능:
-19.86%
6개월 성능:
-43.93%
1년 성능:
-17.03%
1일 변동 폭
$11.40
$12.06
1주일 범위
$10.45
$13.97
52주 변동 폭
$10.45
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
BLCO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
11.50 | 4.83B | 4.79B | -317.00M | -59.00M | -0.91 |
|
ISRG
Intuitive Surgical Inc
|
529.42 | 184.23B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
167.07 | 48.46B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
98.30 | 47.15B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
240.00 | 35.24B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.30 | 16.39B | 3.90B | 392.30M | 288.10M | 1.95 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch & Lomb stock target cut to $15 at H.C. Wainwright By Investing.com - Investing.com South Africa
Bausch & Lomb stock target cut to $15 at H.C. Wainwright - Investing.com Nigeria
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwright & Co. | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Cut by Analyst Amid Tariff Concerns | BLCO Stock News - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Pr - GuruFocus
Bausch + Lomb (BLCO) Shares Plunge After Weak Q1 2025 Results - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Evercore ISI Group - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Wells Fargo | BLCO Stock News - GuruFocus
Bausch + Lomb Corporation (NYSE:BLCO) Q1 2025 Earnings Call Transcript - Insider Monkey
Bausch + Lomb (BLCO) Faces Price Target Cut Amid Financial Press - GuruFocus
Bausch + Lomb (BLCO) Sees Adjusted Price Target Amidst Earnings Update | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Reports Q1 Revenue Slightly Below Expectati - GuruFocus
Bausch + Lomb (BLCO) Price Target Reduced by Citi After Q1 Repor - GuruFocus
Bausch + Lomb (BLCO) Misses Revenue Expectations in Q1, Shares D - GuruFocus
Bausch + Lomb (BLCO) Misses Q1 Estimates, Lowers Growth Outlook - GuruFocus
Bausch & Lomb Reports Weak Start to 2025 as enVista Recall, Tariffs, and Drug Pricing Cause Concerns - Morningstar
Bausch & Lomb Corp SEC 10-Q Report - TradingView
Bausch + Lomb stock hits 52-week low at $10.46 By Investing.com - Investing.com India
Bausch + Lomb stock hits 52-week low at $10.46 - Investing.com Australia
Bausch + Lomb shares tumble as Q1 earnings miss expectations By Investing.com - Investing.com Canada
Bausch + Lomb shares tumble as Q1 earnings miss expectations - Investing.com
Bausch + Lomb Announces First-Quarter 2025 Results - BioSpace
Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Bausch + Lomb Q1 2025 slides: Revenue grows 5% despite enVista recall impact - Investing.com
Bausch + Lomb (BLCO) Updates FY25 Financial Outlook | BLCO Stock News - GuruFocus
Bausch + Lomb: Q1 Earnings Snapshot - Barchart.com
Bausch + Lomb Q1 2025 Financial Results - TradingView
Wells Fargo maintains Bausch & Lomb stock with $15 target By Investing.com - Investing.com Canada
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings - Barchart.com
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall - BioSpace
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb resumes enVista IOL production after recall - Investing.com
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for - MSN
Billionaire Carl Icahn builds 34% economic interest in Bausch Health - Reuters
Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts? - Yahoo Finance
Fitch upgrades Bausch + Lomb rating, maintains evolving watch - Investing.com
Fitch upgrades Bausch + Lomb rating, maintains evolving watch By Investing.com - Investing.com Canada
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg.com
Bausch & Lomb Corp (BLCO) Shares Down 3.1% on Apr 15 - GuruFocus
Bausch & Lomb Agrees to End Vitamin-Patent Suit Ahead of Trial - Bloomberg Law News
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? - Yahoo
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Bausch + Lomb Recalls Certain EnVista Intraocular Lenses - Nasdaq
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & SuppliesSpecialty Segment - Yahoo Finance
Bausch + Lomb Gears Up For Q1 2025 Results Announcement - Finimize
RBC Capital cuts Bausch & Lomb price target to $17, maintains Outperform - Investing.com
Stifel cuts Bausch & Lomb stock target to $15, maintains hold - Investing.com
Lawyers focus on Bausch + Lomb recall investigation | 2025-03-31 | Investing News - Stockhouse
Bausch & Lomb Patents’ Validity Should Go to Trial, Judge Says - Bloomberg Law News
WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty - Baystreet.ca
Wells Fargo cuts Bausch & Lomb stock rating, lowers target to $15 - Investing.com UK
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.05%
5.45%
자본화:
|
볼륨(24시간):